Jing-Jing Xia

A Spatially Controlled Glioblastoma-on-a-Chip for Dissecting Tumor-Immune-Vascular Crosstalk and Bevacizumab Resistance.

Glioblastoma (GBM) is an aggressive brain malignancy with a median survival of only 15 months despite current therapeutic interventions. A major obstacle to effective treatment is the intricate tumor microenvironment (TME), which drives tumor progression and therapy resistance. However, existing in vitro models lack mi...